Reply to 'Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents' by Saad and Buyse
- PMID: 27241134
- DOI: 10.1093/annonc/mdw189
Reply to 'Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents' by Saad and Buyse
Comment in
-
Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'.Ann Oncol. 2016 Aug;27(8):1653. doi: 10.1093/annonc/mdw196. Epub 2016 May 6. Ann Oncol. 2016. PMID: 27154422 No abstract available.
Comment on
-
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.Ann Oncol. 2016 Mar;27(3):373-8. doi: 10.1093/annonc/mdv562. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578738 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
